5-fu therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
5-fu therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
ABSTRACT This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the
benefit of such data for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89 patients (group 1; 228 cycles) revealed that both the
time-concentration product (AUC) for the entire cycle and the half-cycle AUC (AUC0-3 days) were predictive of cycle toxicity. Real-time analysis of individual AUC0-3 days was used to decide
whether to reduce the dose during the second half of the cycle for a total of 249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2
courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0.05) and a statistically significant reduction
was observed in the incidence of toxic cycles (greater than grade 2, group 1 = 20% versus group 2 = 12.4%; 0.02 less than P less than 0.05). Pharmacokinetic follow-up of these patients has
proved to be an objective means to improve therapeutic index significantly. Access through your institution Buy or subscribe This is a preview of subscription content, access via your
institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this
article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in
* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS A RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE OR NAB-PACLITAXEL
COMBINED WITH CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER Article Open access 12 July 2022 INTRAVENOUS LIPOSOMAL IRINOTECAN IN METASTATIC
TRIPLE-NEGATIVE BREAST CANCER AFTER ≥ 2 PRIOR LINES OF CHEMOTHERAPY: A PHASE IB STUDY Article Open access 02 January 2025 PHASE 1 DOSE-ESCALATION STUDY EVALUATING THE SAFETY,
PHARMACOKINETICS, AND CLINICAL ACTIVITY OF OBI-3424 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS Article Open access 12 May 2023 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Centre
Antoine Lacassagne, Nice, France J Santini Authors * J Santini View author publications You can also search for this author inPubMed Google Scholar * G Milano View author publications You
can also search for this author inPubMed Google Scholar * A Thyss View author publications You can also search for this author inPubMed Google Scholar * N Renee View author publications You
can also search for this author inPubMed Google Scholar * P Viens View author publications You can also search for this author inPubMed Google Scholar * P Ayela View author publications You
can also search for this author inPubMed Google Scholar * M Schneider View author publications You can also search for this author inPubMed Google Scholar * F Demard View author publications
You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Santini, J., Milano, G., Thyss, A. _et al._
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. _Br J Cancer_ 59, 287–290 (1989). https://doi.org/10.1038/bjc.1989.59
Download citation * Issue Date: 01 February 1989 * DOI: https://doi.org/10.1038/bjc.1989.59 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get
shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
Trending News
The plastic littering a beach can be tracked to its source* RESEARCH HIGHLIGHT * 15 February 2022 Efforts to clean up beaches could be aided by a model that traces the movement o...
Evolution of darwin’s finches and their beaks revealed by genome sequencingABSTRACT Darwin’s finches, inhabiting the Galápagos archipelago and Cocos Island, constitute an iconic model for studies...
The metatron: an experimental system to study dispersal and metaecosystems for terrestrial organismsABSTRACT Dispersal of organisms generates gene flow between populations. Identifying factors that influence dispersal wi...
Nottingham forest fans make gary neville feelings clear with foul-mouthed chantGARY NEVILLE WAS BANNED BY NOTTINGHAM FOREST FOR THEIR FORMER PREMIER LEAGUE GAME OF THE SEASON AGAINST CHELSEA AT THE C...
Jacqui Webster – The ConversationProfile Articles Activity Professor Jacqui Webster, PhD, RPHNut, is Head of Advocacy Impact and Director of the World He...
Latests News
5-fu therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancerABSTRACT This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous ...
Siburan makes solid ASX debut | The West AustralianThe West Australian Gold and uranium explorer Siburan Resources has made a solid debut on the Australian stock exchange ...
U. S. -vietnam open skies agreement in the cardsU.S.-Vietnam open skies agreement in the cards The United States and Vietnam are moving toward an open skies agreement a...
Javascript support required...
Welsh projects given the green light to develop the latest battery technology for electric vehiclesPress release WELSH PROJECTS GIVEN THE GREEN LIGHT TO DEVELOP THE LATEST BATTERY TECHNOLOGY FOR ELECTRIC VEHICLES * Engl...